Virbac (VIRP) 주식 개요
Virbac SA는 유럽, 북미, 라틴 아메리카, 동아시아, 인도, 아프리카, 중동 및 태평양 지역에서 반려동물과 농장 동물을 위한 다양한 제품과 서비스를 제조 및 판매하고 있습니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 VIRP에 대한 위험이 감지되지 않았습니다.
VIRP Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Virbac SA 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | €350.00 |
| 52주 최고가 | €389.50 |
| 52주 최저가 | €296.00 |
| 베타 | 0.76 |
| 1개월 변동 | -3.98% |
| 3개월 변동 | 1.89% |
| 1년 변동 | 7.36% |
| 3년 변동 | 20.07% |
| 5년 변동 | 31.33% |
| IPO 이후 변동 | 2,748.30% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 07
VIRP: Stable Assumptions And Extraordinary Meeting Will Support Future Upside Repricing
Analysts have maintained their price target for Virbac at €412.88, citing unchanged assumptions around revenue growth, profit margins and future P/E expectations. What's in the News Virbac has scheduled a Special and Extraordinary Shareholders Meeting for June 29, 2026.내러티브 업데이트 • May 24
VIRP: Stable Margins And P/E Assumptions Will Support Future Upside Repricing
Analysts have made a very small adjustment to Virbac's fair value estimate, nudging the price target from €413.00 to around €412.88. This reflects updated fine tuning of revenue growth, profit margin and future P/E assumptions.내러티브 업데이트 • May 09
VIRP: Human Animal Bond Partnership Will Support Future Upside Repricing
Analysts have made a small upward adjustment to their Virbac target, lifting fair value from about €412.33 to €413.00. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.Recent updates
내러티브 업데이트 • Jun 07
VIRP: Stable Assumptions And Extraordinary Meeting Will Support Future Upside Repricing
Analysts have maintained their price target for Virbac at €412.88, citing unchanged assumptions around revenue growth, profit margins and future P/E expectations. What's in the News Virbac has scheduled a Special and Extraordinary Shareholders Meeting for June 29, 2026.내러티브 업데이트 • May 24
VIRP: Stable Margins And P/E Assumptions Will Support Future Upside Repricing
Analysts have made a very small adjustment to Virbac's fair value estimate, nudging the price target from €413.00 to around €412.88. This reflects updated fine tuning of revenue growth, profit margin and future P/E assumptions.내러티브 업데이트 • May 09
VIRP: Human Animal Bond Partnership Will Support Future Upside Repricing
Analysts have made a small upward adjustment to their Virbac target, lifting fair value from about €412.33 to €413.00. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.내러티브 업데이트 • Mar 11
VIRP: Human Animal Bond Partnership Will Support 2026 Outlook Repricing
Analysts have made a small adjustment to their Virbac price target to reflect marginal tweaks in fair value, growth and margin assumptions, trimming it by about €0.50 to €412.33. What's in the News Virbac entered a new partnership with the Human Animal Bond Research Institute to support efforts that strengthen the human animal bond and its impact on companion animal and human health, focusing on science, education and collaboration (Key Developments).내러티브 업데이트 • Feb 25
VIRP: Stable Assumptions And 2026 Guidance Will Support Bullish Repricing
Analysts have maintained their Virbac price target at €412.82, indicating unchanged views on fair value, discount rate, growth assumptions, and margin expectations for the company. What's in the News Virbac entered a partnership with the Human Animal Bond Research Institute (HABRI) to support efforts that strengthen the human animal bond and its impact on companion animal and human health, with a focus on science, education and collaboration (Key Developments).내러티브 업데이트 • Feb 11
VIRP: Stable Inputs And 2026 Guidance Will Support Bullish Repricing
Analysts have kept Virbac's fair value estimate steady at €412.82 per share, with only small technical adjustments to inputs such as the discount rate and assumed future P/E informing this unchanged price target. What's in the News Virbac issued earnings guidance for 2026, including the impact of the Thyronorm acquisition, with revenue growth expected to be between 5.5% and 7.5% at constant rates and scope (Key Developments).내러티브 업데이트 • Jan 26
VIRP: Broad Regional Execution And 2026 Outlook Will Support Bullish Repricing
Narrative Update The analyst price target for Virbac has been raised from €390 to €415, with analysts citing accelerated growth across all regions as the key driver of this change. Analyst Commentary Analysts lifting their price target on Virbac to €415 from €390 are focusing on how the company is executing its growth plans across regions and what that could mean for valuation and risk.내러티브 업데이트 • Jan 07
VIRP: Broad Regional Acceleration Will Support Upgraded Buy Rating Into 2025
Narrative Update on Virbac Analysts have increased their price target on Virbac to €415 from €390, citing what they describe as accelerated growth across all regions as the key driver for their updated view. Analyst Commentary Recent research points to a more constructive stance on Virbac, with analysts raising their price target to €415 from €390 as they reassess the company’s growth profile.내러티브 업데이트 • Dec 23
VIRP: Broad Regional Acceleration Will Sustain Upgraded Buy Rating Through 2025
Analysts have raised their price target on Virbac from EUR 390 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to a higher price target as a reflection of stronger than expected execution in scaling operations across all regions.내러티브 업데이트 • Dec 09
VIRP: Broad Regional Momentum Will Support Upgraded Buy Rating Through 2025
Analysts have raised their price target on Virbac by EUR 25 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Following the recent upgrade, research coverage has focused on the sustainability of Virbac’s growth acceleration and its implications for valuation.내러티브 업데이트 • Nov 25
VIRP: Accelerated Regional Momentum Will Sustain an Upgraded Bullish Outlook for 2025
Analysts have raised Virbac's price target from €390 to €415, citing accelerated growth across all regions as the key driver for their more positive outlook. Analyst Commentary Bullish Takeaways Bullish analysts cite a clear acceleration in Virbac's growth across all geographic regions, which supports a more positive outlook for the company.내러티브 업데이트 • Nov 07
VIRP: Accelerated Regional Expansion Will Drive Upgraded Earnings Outlook Next Year
Narrative Update on Virbac Analysts have raised Virbac's price target from €398 to €403, citing accelerated growth across all regions as the primary driver for this upward revision. Analyst Commentary The most recent research notes reflect increased optimism around Virbac's trajectory, with upward revisions to both rating and price targets.분석 기사 • Oct 05
Is There An Opportunity With Virbac SA's (EPA:VIRP) 43% Undervaluation?
Key Insights Virbac's estimated fair value is €563 based on 2 Stage Free Cash Flow to Equity Virbac's €323 share price...분석 기사 • Sep 17
Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report
Shareholders might have noticed that Virbac SA ( EPA:VIRP ) filed its quarterly result this time last week. The early...분석 기사 • Aug 30
There's Reason For Concern Over Virbac SA's (EPA:VIRP) Price
Virbac SA's ( EPA:VIRP ) price-to-earnings (or "P/E") ratio of 19.3x might make it look like a sell right now compared...분석 기사 • Jun 23
Is There An Opportunity With Virbac SA's (EPA:VIRP) 46% Undervaluation?
Key Insights Virbac's estimated fair value is €601 based on 2 Stage Free Cash Flow to Equity Virbac's €324 share price...분석 기사 • May 18
Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
When close to half the companies in France have price-to-earnings ratios (or "P/E's") below 15x, you may consider...분석 기사 • Apr 30
Virbac (EPA:VIRP) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
새로운 내러티브 • Mar 16
Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals
Strategic R&D investments and facility expansions aim to drive innovation, operational efficiency, and future revenue growth, potentially enhancing profitability.분석 기사 • Jan 24
Earnings Not Telling The Story For Virbac SA (EPA:VIRP)
Virbac SA's ( EPA:VIRP ) price-to-earnings (or "P/E") ratio of 17.9x might make it look like a sell right now compared...분석 기사 • Oct 06
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 47% Undervalued
Key Insights The projected fair value for Virbac is €699 based on 2 Stage Free Cash Flow to Equity Virbac is estimated...분석 기사 • Sep 18
Virbac SA Just Beat Revenue Estimates By 6.0%
It's been a good week for Virbac SA ( EPA:VIRP ) shareholders, because the company has just released its latest...분석 기사 • Aug 31
Unpleasant Surprises Could Be In Store For Virbac SA's (EPA:VIRP) Shares
With a price-to-earnings (or "P/E") ratio of 24x Virbac SA ( EPA:VIRP ) may be sending very bearish signals at the...분석 기사 • Jun 15
Why We Think Virbac SA's (EPA:VIRP) CEO Compensation Is Not Excessive At All
Key Insights Virbac's Annual General Meeting to take place on 21st of June Salary of €379.0k is part of CEO Sebastien...분석 기사 • Jun 10
Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Virbac fair value estimate is €551 Virbac's €363 share price...분석 기사 • May 21
Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
With a price-to-earnings (or "P/E") ratio of 24.2x Virbac SA ( EPA:VIRP ) may be sending bearish signals at the moment...분석 기사 • Mar 22
Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results
Last week saw the newest yearly earnings release from Virbac SA ( EPA:VIRP ), an important milestone in the company's...분석 기사 • Jan 18
Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?
Key Insights The projected fair value for Virbac is €440 based on 2 Stage Free Cash Flow to Equity Virbac's €340 share...분석 기사 • Dec 27
Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up
Virbac SA ( EPA:VIRP ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking...분석 기사 • Oct 19
Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Sep 26
Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?
Key Insights Virbac's estimated fair value is €411 based on 2 Stage Free Cash Flow to Equity Current share price of...분석 기사 • Sep 05
Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...분석 기사 • Jun 20
A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Key Insights The projected fair value for Virbac is €337 based on 2 Stage Free Cash Flow to Equity Current share price...분석 기사 • May 31
Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...분석 기사 • Apr 09
Is Virbac (EPA:VIRP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Feb 28
Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Key Insights The projected fair value for Virbac is €437 based on 2 Stage Free Cash Flow to Equity Virbac's €288 share...분석 기사 • Nov 25
Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Virbac SA ( EPA:VIRP...분석 기사 • Oct 14
Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Aug 07
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Virbac SA ( EPA:VIRP...분석 기사 • Jun 26
These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • May 01
Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate
How far off is Virbac SA ( EPA:VIRP ) from its intrinsic value? Using the most recent financial data, we'll take a look...분석 기사 • Mar 26
We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Jan 26
Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate
How far off is Virbac SA ( EPA:VIRP ) from its intrinsic value? Using the most recent financial data, we'll take a look...분석 기사 • Dec 28
Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...주주 수익률
| VIRP | FR Pharmaceuticals | FR 시장 | |
|---|---|---|---|
| 7D | -0.7% | 4.7% | 0.4% |
| 1Y | 7.4% | -5.9% | 1.9% |
수익률 대 산업: VIRP은 지난 1년 동안 -5.9%의 수익을 기록한 French Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: VIRP은 지난 1년 동안 1.9%를 기록한 French 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| VIRP volatility | |
|---|---|
| VIRP Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 11.2% |
| 10% least volatile stocks in FR Market | 2.8% |
안정적인 주가: VIRP는 지난 3개월 동안 French 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: VIRP의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1968 | 6,442 | Paul Martingell | corporate.virbac.com |
Virbac SA는 유럽, 북미, 라틴 아메리카, 동아시아, 인도, 아프리카, 중동 및 태평양 지역에서 반려동물과 농장 동물을 위한 다양한 제품과 서비스를 제조 및 판매하고 있습니다. 이 회사는 다양한 백신, 항생제, 구충제, 항염증제뿐만 아니라 피부과, 치과, 특수, 진단, 영양, 펫푸드, 의약품을 제공합니다. 수의사, 농부, 반려동물 보호자에게 서비스를 제공합니다.
Virbac SA 기초 지표 요약
| VIRP 기초 통계 | |
|---|---|
| 시가총액 | €2.93b |
| 순이익 (TTM) | €150.89m |
| 매출 (TTM) | €1.46b |
19.4x
주가수익비율(P/E)2.0x
주가매출비율(P/S)VIRP는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| VIRP 손익계산서 (TTM) | |
|---|---|
| 매출 | €1.46b |
| 매출원가 | €487.96m |
| 총이익 | €976.71m |
| 기타 비용 | €825.83m |
| 순이익 | €150.89m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
Sep 17, 2026
| 주당순이익(EPS) | 18.01 |
| 총이익률 | 66.68% |
| 순이익률 | 10.30% |
| 부채/자본 비율 | 22.3% |
VIRP의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Virbac 배당 일정 | |
|---|---|
| 배당락일 | Jul 02 2026 |
| 배당 지급일 | Jul 06 2026 |
| 배당락일까지 남은 일수 | 24 days |
| 배당 지급일까지 남은 일수 | 28 days |
VIRP는 안정적으로 배당을 지급합니까?
VIRP 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/08 06:19 |
| 종가 | 2026/06/05 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Virbac SA는 12명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Delphine Le Louet | Bernstein |
| Laurent Gelebart | BNP Paribas |
| Arnaud Cadart | CIC Market Solutions (ESN) |